Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 9/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109862 | 0.91 | PTGS2 (0.46) | PTGS2RPS6KA3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7537735 | 0.90 | RPS6KA3 (0.43) | PTGS2RPS6KA3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7114909 | 0.89 | PTGS2 (0.49) | PTGS2RPS6KA3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7108675 | 0.89 | PTGS2 (0.49) | PTGS2RPS6KA3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6728545 | 0.88 | PTGS2 (0.47) | PTGS2RPS6KA3PTGS1SLC22A12CYP17A1 | |
| SCHEMBL6729526 | 0.88 | RPS6KA3 (0.47) | PTGS2RPS6KA3PTGS1SLC22A12CYP17A1 | |
| SCHEMBL7541466 | 0.88 | RPS6KA3 (0.48) | PTGS2RPS6KA3SLC22A12 | |
| SCHEMBL7170268 | 0.88 | PTGS2 (0.50) | PTGS2RPS6KA3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7115512 | 0.86 | PTGS2 (0.52) | PTGS2RPS6KA3PTGS1CYP17A1 | |
| SCHEMBL7114724 | 0.85 | RPS6KA3 (0.46) | PTGS2RPS6KA3SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252153-A1 | SUBSTITUTED PIPERIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-10-30 | — | — | EP | claimed |
| WO-2001049676-A1 | SUBSTITUTED PIPERIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-12 | — | — | WO | claimed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885RPS6KA3 1119/4885PIK3CD 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.